The following listing of claims will replace all prior versions and listings of claims in this application.

Listing of Claims:

Claim 1 (previously presented): An antisense compound 8 to 30 nucleobases in length targeted to nucleobases 727 through 868 or nucleobases 899 through 1310 of a nucleic acid molecule encoding TNFR1 (SEQ ID NO: 1), wherein said antisense compound inhibits the expression of TNFR1.

Claim 2 (original): The antisense compound of claim 1 which is an antisense oligonucleotide.

Claims 3-4 (canceled).

Claim 5 (original): The oligonucleotide of claim 2 which comprises at least one modified internucleoside linkage.

Claim 6 (original): The oligonucleotide of claim 5 wherein the modified internucleoside linkage is a phosphorothioate linkage.

Claim 7 (original): The oligonucleotide of claim 2 which comprises at least one modified sugar moiety.

Claim 8 (original): The oligonucleotide of claim 7 wherein the modified sugar moiety is a 2'-o-methoxyethyl sugar moiety.

Claim 9 (original): The oligonucleotide of claim 2 which comprises at least one modified nucleobase.

Claim 10 (original): The oligonucleotide of claim 9 wherein the modified nucleobase is a 5-methylcytosine.

Claim 11 (original): The oligonucleotide of claim 2 which is a chimeric oligonucleotide.

Claim 12 (original): A pharmaceutical composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claim 13 (original): The pharmaceutical composition of claim 12 comprising a colloidal dispersion system.

Claim 14 (original): The pharmaceutical composition of claim 12 wherein the antisense compound is an antisense oligonucleotide.

Claim 15 (previously presented): A method of inhibiting the expression of TNFR1 in cells or tissues comprising contacting said cells or tissues *in vitro* with the antisense compound of claim 1 so that expression of TNFR1 is inhibited.

Claims 16-24 (canceled).